Description:Rabbit polyclonal antibody to NF-kappaB p100Immunogen:KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human NF-kappaB p100. The exact sequence is proprietary.Purification:The antibody was purified by immunogen affinity chromatography.Clonality:PolyclonalForm:Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.Dilution:WB (1/500 - 1/1000), IH (1/100 - 1/200), IF/IC (1/100 - 1/500), IP (1/10 - 1/100)Gene Symbol:NFKB2Alternative Names:LYT10; Nuclear factor NF-kappa-B p100 subunit; DNA-binding factor KBF2; H2TF1; Lymphocyte translocation chromosome 10 protein; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2; Oncogene Lyt-10; Lyt10
Entrez Gene (Human):
4791;
Entrez Gene (Mouse):
18034;
SwissProt (Human):
Q00653;
SwissProt (Mouse):
Q9WTK5;
Storage/Stability:Shipped at 4°C. Upon delivery aliquot and store at -20°C for one year. Avoid freeze/thaw cycles.
-
Western blot analysis of NF-kappaB p100 expression in HEK293T (A), mouse liver (B) whole cell lysates. (Predicted band size: 96 kD; Observed band size: 100 kD)
-
Immunohistochemical analysis of NF-kappaB p100 staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
-
Immunofluorescent analysis of NF-kappaB p100 staining in HEK293T cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.
An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells